Event Details
Agenda
Event Details
Background
Functional bowel disorders represent a major health care burden, with significant impact on the quality of life involving at least 10 to 15 percent of the general population. Recent advances suggest that the field is well positioned for transformative advances in our understanding of the pathophysiology, diagnosis and management of these disorders, which will benefit patients. This workshop will focus on elucidating the research gaps in our current knowledge and how to address these gaps in a timely and effective manner.
Meeting Objectives
Functional bowel disorders represent a major health care burden, with significant impact on the quality of life involving at least 10 to 15 percent of the general population. Recent advances suggest that the field is well positioned for transformative advances in our understanding of the pathophysiology, diagnosis, and management of these disorders, which will benefit patients. This workshop will focus on elucidating the research gaps in our current knowledge and how to address these gaps in a timely and effective manner.
Planning Committee
Chair
John Wiley, M.D.
University of Michigan
Members
Lin Chang, M.D.
University of California, Los Angeles
Carlo Di Lorenzo, M.D.
The Ohio State University
Gary Mawe, Ph.D.
University of Vermont
Pankaj (Jay) Pasricha, M.D.
Johns Hopkins Medicine
NIH Staff
Jill Carrington, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Frank A. Hamilton, M.D., M.P.H.
NIDDK
Rebecca Van Raaphorst, M.P.H.
NIDDK
Registration Deadline
June 19, 2016
Agenda
June 23, 2016
- 8:00 a.m. – 8:05 a.m.
- Welcoming Remarks
Griffin P. Rodgers, M.D., M.A.C.P., Director, NIDDK
- 8:05 a.m. – 8:15 a.m.
- FBD: Prevalence and Economic Burden
Frank Hamilton, M.D., M.P.H.
- 8:15 a.m. – 8:30 a.m.
- Introductory Remarks–Functional Bowel Disorders: Where Are We Now, Where Are We Headed?
Emeran Mayer
Session 1, Part 1: Pathophysiology: Neuromuscular Dysfunction in FBD: Neural, Muscular, Interstitial Cells of Cajal and Glia
Moderators: Michael Camilleri and Gary Mawe
- 8:30 a.m. – 8:50 a.m.
- FBD: Evidence for Dysmotility
William Hasler
- 8:50 a.m. – 9:10 a.m.
- Enteric Nervous System: Myenteric and Submucous Plexi
Gary Mawe
- 9:10 a.m. – 9:30 a.m.
- Interstitial Cells of Cajal and Smooth Muscle: Role in FBD
Kenton Sanders
- 9:30 a.m. – 9:50 a.m.
- Glia: Control Centers or Active Bystanders in FBD?
Keith Sharkey
- 9:50 a.m. – 10:05 a.m.
- Panel Discussion: What Are the Gaps and Possible Solutions?
- 10:05 a.m. – 10:20 a.m.
- Break
Session 1, Part 2: Pathophysiology: Neuromuscular Dysfunction in FBD: Neural, Muscular, Interstitial Cells of Cajal and Glia
Moderators: Emeran Mayer and Gianrico Farrugia
- 10:20 a.m. – 10:40 a.m.
- The Role of Animal Models in FBD Research
Beverley Greenwood-Van Meerveld
- 10:40 a.m. – 11:00 a.m.
- Visceral Hypersensitivity: Role of Intestinal Barrier Dysfunction and Altered Permeability
Muriel Larauche
- 11:00 a.m. – 11:20 a.m.
- Visceral Hypersensitivity: Role of Primary Afferent Neurons and Spinal Pathways
Steve Vanner
- 11:20 a.m. – 11:40 a.m.
- Visceral Hypersensitivity: Evidence for Altered Regulation in Brain Circuits
Kirsten Tillisch
- 11:40 a.m. – 12:00 p.m.
- Panel Discussion: Gaps and Possible Solutions
- 12:00 p.m. – 1:00 p.m.
- Lunch
Session 2, Part 1: FBD: Pathogenesis
Moderators: Magnus Simren and Elena Verdu
- 1:00 p.m. – 1:20 p.m.
- Post-infection Mechanisms in FBD
Magnus Simren
- 1:20 p.m. – 1:40 p.m.
- Neuroimmune Mechanisms in FBD: Role of Cellular and Pro-inflammatory Mediators
Terez Shea-Donohue
- 1:40 p.m. – 2:00 p.m.
- Intraluminal Factors in FBD: Microbiota (Bacteria, Viruses, etc.)
Tor Savidge
- 2:00 p.m. – 2:20 p.m.
- Intraluminal Factors in FBD: Bile Salts and Other Molecular Species
Michael Camilleri
- 2:20 p.m. – 2:40 p.m.
- Dietary Triggers in FBD: FODMAP and Other Food Sensitivities
Elena Verdu
- 2:40 p.m. – 3:00 p.m.
- Environmental Factors and Coping in FBD
Rona Levy
- 3:00 p.m. – 3:15 p.m.
- Panel Discussion: Gaps and Possible Solutions
- 3:15 p.m. – 3:30 p.m.
- Break
Session 2, Part 2: FBD: Pathogenesis
Moderators: Nicholas Verne and Miguel Saps
- 3:30 p.m. – 3:50 p.m.
- Genetic Associations in FBD
Yuri Saito
- 3:50 p.m. – 4:10 p.m.
- Epigenetic Mechanisms in FBD
John Wiley
- 4:10 p.m. – 4:30 p.m.
- Early Life Stress and Transgenerational Mechanisms in FBD
Adrian Miranda
- 4:30 p.m. – 4:50 p.m.
- Gender and FBD
Margaret Heitkemper
- 4:50 p.m. – 5:10 p.m.
- Psychosocial Factors and Their Relationship to Functional Bowel Disorders
Doug Drossman
- 5:10 p.m. – 5:30 p.m.
- Panel Discussion: Gaps and Possible Solutions
- 5:30 p.m.
- Adjournment
June 24, 2016
Session 3: Current and Emerging Strategies to Manage FBDs
Moderators: Carlo Di Lorenzo and William Whitehead
- 8:00 a.m. – 8:20 a.m.
- Current and Emerging Treatments of FBD: Pediatrics
Carlo Di Lorenzo
- 8:20 a.m. – 8:40 a.m.
- Current and Emerging Treatments of FBD: Adults
William Chey
- 8:40 a.m. – 9:00 a.m.
- Complementary and Alternative Approaches to Manage FBD
Miranda van Tilburg
- 9:00 a.m. – 9:20 a.m.
- Biologic Phenotyping in FBDs
Lin Chang
- 9:20 a.m. – 9:35 a.m.
- Panel Discussion: Gaps and Possible Solutions
- 9:35 a.m. – 9:50 a.m.
- Break
Session 4: Addressing the Gaps: Application of Next-generation Genomics, Epigenomics, Proteomics, and Pharmacogenomics to Diagnose and Treat FBD
Moderators: Lin Chang and John Wiley
- 9:50 a.m. – 10:20 a.m.
- Future Directions in Genomics, Epigenomics, and Proteomics to Identify Novel Diagnostic Biomarkers and Therapeutic Targets
Dimitrios Iliopoulos
- 10:20 a.m. – 10:50 a.m.
- The Emergence of Pharmacogenomics and Its Application to FBD
Wolfgang Sadee
- 10:50 a.m. – 11:20 a.m.
- Strategies to Strengthen FBD Research and Lessons from Federally Supported Initiatives
Jay Pasricha
- 11:20 a.m. – 11:50 a.m.
- FBD: The Road to Precision Medicine
Gianrico Farrugia
- 11:50 a.m. – 12:15 p.m.
- Panel Discussion: Future Directions and How Do We Get There?
- 12:15 p.m. – 12:30 p.m.
- Closing Remarks
John Wiley
- 12:30 p.m.
- Adjournment
